SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, has appointed Sarah M. Romano as chief financial officer, effective Aug. 3, 2026. Based in the United States, Romano brings more than two decades of finance leadership experience in the medical technology and life sciences sectors. Her appointment is expected to help lead the company’s financial operations as it advances its global expansion strategy, including pursuit of U.S. FDA approval for its SSi Mantra surgical robotic system.
Romano most recently served as chief financial officer of Vicarious Surgical, where she led financial and operational initiatives to reduce cash burn, strengthen the balance sheet and support strategic objectives. She previously held CFO roles at Entero Therapeutics and Kiora Pharmaceuticals, raising more than $100 million through public and private financings while overseeing strategic transactions, SEC reporting and investor relations. Her experience in capital raising and financial stewardship is particularly relevant as SSII navigates the regulatory and commercial milestones ahead.
The announcement comes as SSII continues to develop its proprietary SSi Mantra surgical robotic system and its comprehensive suite of SSi Mudra surgical instruments, which support a variety of procedures including cardiac surgery. The company, headquartered in India but incorporated in the United States, aims to make robotic surgery affordable and accessible to a larger segment of the global population. The pursuit of FDA approval for the SSi Mantra system is a critical step in expanding its presence in the U.S. market.
For more details on the announcement, the full press release is available at https://ibn.fm/pAqlP. Further information about SS Innovations and its technologies can be found through the company's official communications.
The addition of Romano to the executive team signals SSII's commitment to strengthening its financial foundation as it scales operations. Her track record in the medical technology and life sciences sectors, combined with her experience in public company finance, positions her to support the company's strategic objectives, including potential capital raises and regulatory milestones. With Romano at the helm of finance, SSII is poised to advance its mission of delivering cost-effective surgical robotic solutions globally.
